Loading
Takayuki Ueno is a breast surgeon whose translational work links tumour biology to neoadjuvant response.
Takayuki Ueno is a breast surgical oncologist at the Cancer Institute Hospital of JFCR in Tokyo. He combines surgical practice with translational research on immune and genomic predictors of response to neoadjuvant therapy, linking tumour biology to how breast cancers respond before surgery. His publications include a review of biomarkers of neoadjuvant and adjuvant endocrine therapy for ER-positive, HER2-negative breast cancer, a study of neoadjuvant palbociclib in operable hormone receptor-positive breast cancer, and a review of local management after neoadjuvant treatment. His interests are breast surgery, neoadjuvant therapy and translational research.
| Title | Journal | Year |
|---|---|---|
| Biomarkers of neoadjuvant/adjuvant endocrine therapy for ER-positive/HER2-negative breast cancer | Chinese Clinical Oncology | 2020 |
| Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer | Endocrine-Related Cancer | 2025 |
| Local management after neoadjuvant treatment for breast cancer | Chinese Clinical Oncology | 2020 |
Shares Cancer Institute Hospital of JFCR, HR-positive / HER2-negative breast cancer.
Shares Pathologic complete response (pCR), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Pathologic complete response (pCR), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Pathologic complete response (pCR), Triple-negative breast cancer (TNBC).
Shares Pathologic complete response (pCR), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Pathologic complete response (pCR), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Pathologic complete response (pCR), Triple-negative breast cancer (TNBC).
Shares Pathologic complete response (pCR), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.